RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+6.51%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$251M
AUM Growth
–
Cap. Flow
+$251M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
29.9%
Holding
83
New
83
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$10.2M |
| 2 |
CELG
Celgene Corp
CELG
|
$8.28M |
| 3 |
Gilead Sciences
GILD
|
$8.19M |
| 4 |
CVS Health
CVS
|
$7.66M |
| 5 |
Biogen
BIIB
|
$7.55M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 84.16% |
| 2 | Financials | 1.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Elevance Health
ELV
$72.4B
| $2.96M | 1.16% |
+32,000
| New | +$2.96M |
|
|
INFI
27
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $2.9M | 1.13% |
+210,000
| New | +$2.9M |
|
28
Cencora
COR
$57.2B
| $2.81M | 1.1% |
+40,000
| New | +$2.81M |
|
29
Zimmer Biomet
ZBH
$20.8B
| $2.8M | 1.09% |
+30,900
| New | +$2.8M |
|
30
Thermo Fisher Scientific
TMO
$183B
| $2.78M | 1.09% |
+25,000
| New | +$2.78M |
|
31
Insulet
PODD
$24.2B
| $2.78M | 1.09% |
+75,000
| New | +$2.78M |
|
|
AGN
32
DELISTED
ALLERGAN INC
AGN
| $2.78M | 1.09% |
+25,000
| New | +$2.78M |
|
33
Becton Dickinson
BDX
$54.3B
| $2.76M | 1.08% |
+25,625
| New | +$2.76M |
|
34
Johnson & Johnson
JNJ
$429B
| $2.75M | 1.07% |
+30,000
| New | +$2.75M |
|
|
THOR
35
DELISTED
THORATEC CORPORATION
THOR
| $2.75M | 1.07% |
+75,000
| New | +$2.75M |
|
36
Dynavax Technologies
DVAX
$1.19B
| $2.74M | 1.07% |
+140,000
| New | +$2.74M |
|
|
AET
37
DELISTED
Aetna Inc
AET
| $2.74M | 1.07% |
+40,000
| New | +$2.74M |
|
38
DexCom
DXCM
$30.9B
| $2.73M | 1.07% |
+308,000
| New | +$2.73M |
|
|
VAR
39
DELISTED
Varian Medical Systems, Inc.
VAR
| $2.72M | 1.06% |
+39,913
| New | +$2.72M |
|
40
HCA Healthcare
HCA
$95.4B
| $2.62M | 1.03% |
+55,000
| New | +$2.62M |
|
|
PRXL
41
DELISTED
Parexel International Corp
PRXL
| $2.62M | 1.02% |
+58,000
| New | +$2.62M |
|
|
CYBX
42
DELISTED
CYBERONICS INC
CYBX
| $2.62M | 1.02% |
+40,000
| New | +$2.62M |
|
43
Teva Pharmaceuticals
TEVA
$21.5B
| $2.61M | 1.02% |
+65,000
| New | +$2.61M |
|
44
Baxter International
BAX
$12.1B
| $2.57M | 1.01% |
+68,117
| New | +$2.57M |
|
|
STJ
45
DELISTED
St Jude Medical
STJ
| $2.48M | 0.97% |
+40,000
| New | +$2.48M |
|
46
Cigna
CI
$80.2B
| $2.36M | 0.92% |
+27,000
| New | +$2.36M |
|
47
Agilent Technologies
A
$35.5B
| $2.29M | 0.89% |
+55,920
| New | +$2.29M |
|
|
OCR
48
DELISTED
OMNICARE INC
OCR
| $2.23M | 0.87% |
+37,000
| New | +$2.23M |
|
|
HPTX
49
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
| $2.22M | 0.87% |
+110,000
| New | +$2.22M |
|
50
Celldex Therapeutics
CLDX
$1.57B
| $2.18M | 0.85% |
+6,000
| New | +$2.18M |
|